ECE2016 Eposter Presentations Diabetes therapy (44 abstracts)
Lixisenatide effects on liver function, lipids and blood pressure levels
María del Mar Roca-Rodríguez 1 , Gonzalo Piédrola-Maroto 2 , María Teresa Muros de Fuentes 2 , Miguel Quesada-Charneco 3 , Silvia Maraver-Selfa 4 , M José Tapia-Guerrero 4 , Daniel Cepero-García 5 , Rosa Orduña-Espinosa 3 , Joaquín Pechuán-Asensio 6 , Elena Ferrándiz-Millón 5 , Purificación Galera-Martínez 2 , Mercedes Vázquez-Gutiérrez 5 & Isabel Mancha-Doblas 4
1Department of Endocrinology, La Linea Hospital, Cadiz, Spain; 2Department of Endocrinology, Virgen de las Nieves Hospital, Granada, Spain; 3Department of Endocrinology, San Cecilio Hospital, Granada, Spain; 4Department of Endocrinology, Virgen de la Victoria and Regional Hospitals, Malaga, Spain; 5Department of Endocrinology, Torrecardenas Hospital, Almeria, Spain; 6Endocrinology private office, Granada, Spain.
Introduction: New diabetes treatments, such as lixisenatide, improve global metabolic status beyond glycemic control.
Aim: To evaluate lixisenatide effects on liver function, lipids and blood pressure levels in type 2 diabetes and obese patients attended in endocrinology offices.
Material and method: This is a prospective study with a sample of 106 patients with type 2 diabetes and obesity. In an intra-subject analysis, clinical and analytical data were evaluated at baseline and after lixisenatide treatment.
Results: We studied 106 patients (51.9% women) with type 2 diabetes and obesity. Average age was 57.9±1.1 years and average duration of diabetes was 11.1±0.7 years. At baseline, 66% of the patients used insulin. We re-evaluated the patients 3.8±0.2 months after treatment with lixisenatide. We found significant improvements in weight (P<0.001), bmi (P<0.001), wc (P=0.002), sbp (P<0.001), dbp (P=0.001), fasting glucose (P<0.001), hba1c (P<0.001), total-chol (P<0.001), ldl-chol (P=0.040) tg (P=0.047), got (P=0.022), insulin units (P=0.045), hypertension drugs (P<0.001), and lipids drugs (P<0.001). Bp and lipids improvements were still significant in the hypertension and lipid treated subgroups (sbp, P=0.001; dbp, P=0.005; total-chol, P<0.001, ldl-chol, P=0.013 and tg P=0.014), while only the decrease of sbp (P=0.036) remained significant in the subgroup of patients without hypertension or lipid-lowering therapy.
Conclusions: 1) We found significant improvement of anthropometric parameters and glycemic control in terms of fasting glucose and hba1c. 2) Significant decrease of bp, got and lipid profile and less insulin requirements were observed.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more